Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 105 | 2024 | 5671 | 4.910 |
Why?
|
Graft vs Host Disease | 88 | 2024 | 3029 | 4.860 |
Why?
|
Transplantation Conditioning | 45 | 2024 | 1590 | 2.670 |
Why?
|
Transplantation, Homologous | 60 | 2024 | 4806 | 2.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2021 | 1640 | 1.630 |
Why?
|
Hematologic Neoplasms | 30 | 2021 | 1896 | 1.360 |
Why?
|
Interleukin-2 | 13 | 2023 | 1889 | 1.120 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2024 | 3613 | 1.090 |
Why?
|
Leukemia, Promyelocytic, Acute | 9 | 2024 | 251 | 0.980 |
Why?
|
Myelodysplastic Syndromes | 10 | 2024 | 1394 | 0.860 |
Why?
|
Stem Cell Transplantation | 8 | 2021 | 1600 | 0.680 |
Why?
|
Cord Blood Stem Cell Transplantation | 7 | 2019 | 305 | 0.680 |
Why?
|
Recurrence | 31 | 2023 | 8465 | 0.640 |
Why?
|
Hepatic Veno-Occlusive Disease | 7 | 2022 | 220 | 0.620 |
Why?
|
Tacrolimus | 13 | 2023 | 733 | 0.610 |
Why?
|
T-Lymphocytes, Regulatory | 16 | 2022 | 3080 | 0.610 |
Why?
|
Lymphocyte Transfusion | 4 | 2021 | 232 | 0.520 |
Why?
|
Leukemia | 7 | 2024 | 1522 | 0.510 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1405 | 0.500 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1768 | 0.500 |
Why?
|
Survival Analysis | 26 | 2019 | 10090 | 0.450 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 7 | 2013 | 263 | 0.450 |
Why?
|
Sirolimus | 10 | 2019 | 1533 | 0.450 |
Why?
|
Adult | 119 | 2024 | 221177 | 0.430 |
Why?
|
Disease-Free Survival | 27 | 2018 | 6814 | 0.420 |
Why?
|
Myeloablative Agonists | 9 | 2018 | 209 | 0.410 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2218 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11742 | 0.400 |
Why?
|
Middle Aged | 116 | 2024 | 220895 | 0.390 |
Why?
|
Aged | 91 | 2024 | 169289 | 0.380 |
Why?
|
Steroids | 8 | 2023 | 929 | 0.380 |
Why?
|
Survival Rate | 17 | 2024 | 12725 | 0.370 |
Why?
|
Vidarabine | 8 | 2021 | 336 | 0.370 |
Why?
|
Lymphoma | 7 | 2017 | 1901 | 0.360 |
Why?
|
Busulfan | 9 | 2022 | 258 | 0.360 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2018 | 418 | 0.350 |
Why?
|
Endpoint Determination | 1 | 2013 | 590 | 0.340 |
Why?
|
Graft Survival | 10 | 2014 | 3819 | 0.330 |
Why?
|
BK Virus | 2 | 2020 | 123 | 0.320 |
Why?
|
Humans | 166 | 2024 | 761504 | 0.320 |
Why?
|
Recovery of Function | 2 | 2019 | 2979 | 0.310 |
Why?
|
B-Cell Activating Factor | 5 | 2014 | 115 | 0.310 |
Why?
|
Young Adult | 51 | 2024 | 59243 | 0.310 |
Why?
|
Myeloproliferative Disorders | 5 | 2022 | 613 | 0.310 |
Why?
|
Graft vs Leukemia Effect | 3 | 2020 | 121 | 0.310 |
Why?
|
T-Lymphocytes | 8 | 2021 | 10194 | 0.310 |
Why?
|
Methotrexate | 12 | 2018 | 1719 | 0.310 |
Why?
|
Male | 120 | 2024 | 360804 | 0.300 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 857 | 0.300 |
Why?
|
Transplantation, Autologous | 10 | 2022 | 2115 | 0.290 |
Why?
|
Antilymphocyte Serum | 3 | 2018 | 487 | 0.290 |
Why?
|
Killer Cells, Natural | 8 | 2022 | 2200 | 0.290 |
Why?
|
Female | 120 | 2024 | 392644 | 0.280 |
Why?
|
Chronic Disease | 26 | 2023 | 9318 | 0.280 |
Why?
|
Iron Overload | 4 | 2014 | 239 | 0.280 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2022 | 4580 | 0.280 |
Why?
|
Gene Expression Regulation, Leukemic | 3 | 2021 | 651 | 0.270 |
Why?
|
Leukocyte Count | 5 | 2019 | 1596 | 0.260 |
Why?
|
Quinazolinones | 2 | 2019 | 221 | 0.260 |
Why?
|
Leukocytes | 1 | 2014 | 2026 | 0.260 |
Why?
|
Immunosuppressive Agents | 10 | 2018 | 4174 | 0.260 |
Why?
|
Neoplasm, Residual | 4 | 2022 | 1008 | 0.250 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2021 | 1374 | 0.250 |
Why?
|
Fetal Blood | 5 | 2019 | 1347 | 0.240 |
Why?
|
Prognosis | 27 | 2021 | 29625 | 0.240 |
Why?
|
Purines | 2 | 2019 | 607 | 0.230 |
Why?
|
T-Lymphocyte Subsets | 4 | 2019 | 1802 | 0.230 |
Why?
|
Retrospective Studies | 47 | 2024 | 80636 | 0.230 |
Why?
|
Adolescent | 42 | 2024 | 88319 | 0.220 |
Why?
|
Treatment Outcome | 44 | 2024 | 64680 | 0.220 |
Why?
|
Leukemia, Myeloid | 5 | 2021 | 694 | 0.220 |
Why?
|
Lymphocyte Count | 5 | 2019 | 778 | 0.210 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2017 | 1551 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Sex Factors | 2 | 2016 | 10552 | 0.210 |
Why?
|
Chromosome Deletion | 2 | 2018 | 1386 | 0.210 |
Why?
|
Ferritins | 5 | 2014 | 598 | 0.200 |
Why?
|
Daunorubicin | 5 | 2015 | 156 | 0.200 |
Why?
|
Antigens, CD34 | 1 | 2024 | 658 | 0.200 |
Why?
|
Models, Biological | 2 | 2015 | 9469 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2020 | 4369 | 0.190 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 694 | 0.190 |
Why?
|
Tretinoin | 6 | 2015 | 519 | 0.190 |
Why?
|
HLA Antigens | 5 | 2017 | 1328 | 0.190 |
Why?
|
Proportional Hazards Models | 4 | 2015 | 12463 | 0.180 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 125 | 0.180 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 209 | 0.180 |
Why?
|
Treatment Failure | 2 | 2024 | 2645 | 0.180 |
Why?
|
Boronic Acids | 3 | 2014 | 915 | 0.180 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1469 | 0.180 |
Why?
|
Models, Theoretical | 1 | 2012 | 3575 | 0.170 |
Why?
|
Smallpox Vaccine | 2 | 2010 | 77 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 269 | 0.170 |
Why?
|
Drug Resistance | 3 | 2019 | 1596 | 0.160 |
Why?
|
Dioxygenases | 1 | 2021 | 345 | 0.160 |
Why?
|
DNA, Mitochondrial | 1 | 2024 | 865 | 0.160 |
Why?
|
Lymphocyte Activation | 6 | 2022 | 5486 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 12 | 2021 | 6484 | 0.160 |
Why?
|
Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
Transplantation Chimera | 4 | 2015 | 594 | 0.160 |
Why?
|
Pyrazines | 3 | 2014 | 1201 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 467 | 0.160 |
Why?
|
Incidence | 12 | 2023 | 21353 | 0.160 |
Why?
|
Vaccinia virus | 2 | 2010 | 331 | 0.150 |
Why?
|
Combined Modality Therapy | 7 | 2021 | 8529 | 0.150 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9606 | 0.150 |
Why?
|
Lymphocyte Depletion | 3 | 2016 | 602 | 0.150 |
Why?
|
Piperidines | 3 | 2021 | 1656 | 0.150 |
Why?
|
Acute Disease | 11 | 2024 | 7237 | 0.150 |
Why?
|
Immunoglobulins | 2 | 2017 | 853 | 0.140 |
Why?
|
Tissue Donors | 10 | 2024 | 2331 | 0.140 |
Why?
|
Virus Activation | 1 | 2019 | 322 | 0.140 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 306 | 0.140 |
Why?
|
Polyomavirus Infections | 1 | 2019 | 194 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1978 | 0.140 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 123 | 0.140 |
Why?
|
Age Factors | 9 | 2024 | 18395 | 0.130 |
Why?
|
Tumor Virus Infections | 1 | 2019 | 438 | 0.130 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 68 | 0.130 |
Why?
|
Bone Marrow Transplantation | 4 | 2023 | 2693 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 191 | 0.130 |
Why?
|
Lymphoma, Follicular | 1 | 2020 | 457 | 0.130 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2018 | 237 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3617 | 0.130 |
Why?
|
Research Design | 1 | 2012 | 6180 | 0.130 |
Why?
|
Histocompatibility Testing | 6 | 2015 | 712 | 0.130 |
Why?
|
Skin Diseases | 3 | 2020 | 1094 | 0.130 |
Why?
|
Pyrazoles | 3 | 2024 | 2009 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2017 | 1405 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 10209 | 0.120 |
Why?
|
Blood Donors | 3 | 2013 | 345 | 0.120 |
Why?
|
Prednisone | 3 | 2018 | 1563 | 0.120 |
Why?
|
Stem Cell Factor | 1 | 2015 | 195 | 0.120 |
Why?
|
Interleukin-7 | 1 | 2015 | 143 | 0.120 |
Why?
|
Immunologic Memory | 3 | 2017 | 1359 | 0.120 |
Why?
|
H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 587 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1494 | 0.110 |
Why?
|
Isoantibodies | 3 | 2009 | 674 | 0.110 |
Why?
|
Diarrhea | 1 | 2021 | 1318 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2016 | 1745 | 0.110 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
Pyrimidines | 3 | 2024 | 3028 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2917 | 0.110 |
Why?
|
Tandem Repeat Sequences | 1 | 2014 | 180 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1606 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9280 | 0.110 |
Why?
|
Aged, 80 and over | 13 | 2019 | 58976 | 0.110 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39106 | 0.100 |
Why?
|
Histocompatibility | 2 | 2012 | 317 | 0.100 |
Why?
|
Viremia | 2 | 2019 | 707 | 0.100 |
Why?
|
Whole-Body Irradiation | 2 | 2018 | 433 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2825 | 0.100 |
Why?
|
Antibodies, Monoclonal | 5 | 2022 | 9177 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
Pulmonary Edema | 2 | 2014 | 409 | 0.100 |
Why?
|
Homeostasis | 3 | 2013 | 3323 | 0.100 |
Why?
|
B-Lymphocytes | 4 | 2014 | 4758 | 0.100 |
Why?
|
Comorbidity | 2 | 2019 | 10508 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.090 |
Why?
|
Remission Induction | 6 | 2019 | 2396 | 0.090 |
Why?
|
Minor Histocompatibility Antigens | 2 | 2010 | 293 | 0.090 |
Why?
|
Community Networks | 1 | 2013 | 201 | 0.090 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 361 | 0.090 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 265 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1924 | 0.090 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2014 | 495 | 0.090 |
Why?
|
Antineoplastic Agents | 6 | 2017 | 13639 | 0.090 |
Why?
|
Salvage Therapy | 3 | 2012 | 1264 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 974 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4244 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1093 | 0.090 |
Why?
|
Tissue Preservation | 1 | 2011 | 174 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2008 | 1378 | 0.090 |
Why?
|
Mutation | 7 | 2024 | 30052 | 0.090 |
Why?
|
Adenine | 3 | 2021 | 987 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4740 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1880 | 0.080 |
Why?
|
Cohort Studies | 12 | 2018 | 41487 | 0.080 |
Why?
|
Erythema | 1 | 2010 | 262 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2017 | 5869 | 0.080 |
Why?
|
Immunophenotyping | 5 | 2016 | 1870 | 0.080 |
Why?
|
Chromosomes, Human, Y | 1 | 2010 | 161 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 686 | 0.080 |
Why?
|
Iron | 3 | 2014 | 1793 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 970 | 0.080 |
Why?
|
Time Factors | 11 | 2021 | 39967 | 0.080 |
Why?
|
Premedication | 2 | 2008 | 246 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 293 | 0.080 |
Why?
|
Antibodies | 2 | 2017 | 2418 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1092 | 0.070 |
Why?
|
Multiple Myeloma | 2 | 2021 | 5146 | 0.070 |
Why?
|
Lymphoproliferative Disorders | 1 | 2011 | 531 | 0.070 |
Why?
|
B-Lymphocyte Subsets | 1 | 2009 | 239 | 0.070 |
Why?
|
Prospective Studies | 12 | 2022 | 54425 | 0.070 |
Why?
|
Thymus Gland | 2 | 2010 | 1243 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12059 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 2 | 2011 | 3396 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
Fever | 2 | 2014 | 1618 | 0.070 |
Why?
|
Core Binding Factors | 1 | 2006 | 29 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 198 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4484 | 0.070 |
Why?
|
Telomerase | 1 | 2011 | 745 | 0.070 |
Why?
|
Risk | 5 | 2011 | 9610 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 828 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5671 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 2010 | 756 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 2803 | 0.060 |
Why?
|
Antigens, CD1 | 1 | 2008 | 439 | 0.060 |
Why?
|
Idarubicin | 2 | 2015 | 59 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 647 | 0.060 |
Why?
|
Algorithms | 2 | 2024 | 14031 | 0.060 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 106 | 0.060 |
Why?
|
Integrins | 1 | 2009 | 834 | 0.060 |
Why?
|
Living Donors | 1 | 2009 | 641 | 0.060 |
Why?
|
Antigens, CD | 4 | 2022 | 4003 | 0.060 |
Why?
|
Intestinal Diseases | 1 | 2009 | 504 | 0.060 |
Why?
|
Hematologic Diseases | 2 | 2019 | 496 | 0.060 |
Why?
|
Risk Factors | 10 | 2018 | 74206 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1141 | 0.060 |
Why?
|
Vaccination | 2 | 2022 | 3384 | 0.060 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2004 | 58 | 0.060 |
Why?
|
Syndrome | 3 | 2018 | 3267 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 1 | 2011 | 1844 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1866 | 0.060 |
Why?
|
Receptors, Interleukin-2 | 1 | 2005 | 562 | 0.060 |
Why?
|
Risk Assessment | 4 | 2019 | 23995 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 2010 | 831 | 0.050 |
Why?
|
Developing Countries | 2 | 2013 | 2885 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2014 | 2747 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 891 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2021 | 12341 | 0.050 |
Why?
|
Cryopreservation | 2 | 2021 | 728 | 0.050 |
Why?
|
Child | 9 | 2023 | 80153 | 0.050 |
Why?
|
Uruguay | 2 | 2013 | 104 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1036 | 0.050 |
Why?
|
Blood Platelets | 1 | 2013 | 2479 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7048 | 0.050 |
Why?
|
Diet | 1 | 2021 | 8075 | 0.050 |
Why?
|
Stomatitis | 1 | 2005 | 271 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 98 | 0.050 |
Why?
|
Mouth Mucosa | 1 | 2005 | 432 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2019 | 2547 | 0.050 |
Why?
|
United States | 4 | 2021 | 72334 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 336 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10445 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4511 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15842 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5112 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2477 | 0.050 |
Why?
|
Transplantation Immunology | 2 | 2016 | 532 | 0.050 |
Why?
|
Neoplasms | 2 | 2007 | 22170 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Melphalan | 1 | 2022 | 420 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3624 | 0.050 |
Why?
|
Cytokines | 3 | 2021 | 7396 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5796 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2006 | 1393 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 899 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2012 | 5305 | 0.040 |
Why?
|
Injections, Intradermal | 2 | 2010 | 116 | 0.040 |
Why?
|
Mexico | 2 | 2013 | 764 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2010 | 364 | 0.040 |
Why?
|
Antibody Formation | 2 | 2017 | 1395 | 0.040 |
Why?
|
Disease Progression | 5 | 2016 | 13506 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 3065 | 0.040 |
Why?
|
Nitriles | 1 | 2024 | 971 | 0.040 |
Why?
|
Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2003 | 921 | 0.040 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2018 | 57 | 0.040 |
Why?
|
Vaccines, Attenuated | 2 | 2010 | 315 | 0.040 |
Why?
|
Injections, Intramuscular | 2 | 2010 | 554 | 0.040 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 76 | 0.040 |
Why?
|
Brazil | 2 | 2013 | 1230 | 0.040 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3156 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2850 | 0.040 |
Why?
|
Forkhead Transcription Factors | 3 | 2011 | 1616 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4431 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3162 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3801 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6343 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 385 | 0.040 |
Why?
|
Administration, Oral | 2 | 2019 | 4021 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 938 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2691 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 964 | 0.030 |
Why?
|
Spleen | 1 | 2023 | 2295 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6485 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3245 | 0.030 |
Why?
|
Immune Tolerance | 2 | 2019 | 2303 | 0.030 |
Why?
|
Karyotyping | 2 | 2011 | 1171 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2016 | 159 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1827 | 0.030 |
Why?
|
Antibody Specificity | 2 | 2011 | 1060 | 0.030 |
Why?
|
Immunotherapy | 2 | 2023 | 4652 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2161 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2510 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2626 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 878 | 0.030 |
Why?
|
Food Supply | 1 | 2021 | 544 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2016 | 18965 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2015 | 284 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2014 | 22176 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2014 | 27 | 0.030 |
Why?
|
Lymphocytes | 2 | 2014 | 2612 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 833 | 0.030 |
Why?
|
Interleukin-17 | 1 | 2020 | 912 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 781 | 0.030 |
Why?
|
Aging | 2 | 2010 | 8708 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 172 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2449 | 0.030 |
Why?
|
Infant | 3 | 2023 | 36192 | 0.030 |
Why?
|
Liver | 3 | 2016 | 7529 | 0.030 |
Why?
|
Latin America | 1 | 2014 | 410 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1659 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3810 | 0.030 |
Why?
|
Child, Preschool | 3 | 2023 | 42230 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 599 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2012 | 15631 | 0.030 |
Why?
|
DNA, Viral | 1 | 2019 | 2202 | 0.030 |
Why?
|
Chile | 1 | 2013 | 256 | 0.020 |
Why?
|
Models, Statistical | 1 | 2007 | 5079 | 0.020 |
Why?
|
Anthracyclines | 1 | 2014 | 284 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2016 | 1341 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1217 | 0.020 |
Why?
|
Death | 1 | 2016 | 676 | 0.020 |
Why?
|
Saliva | 1 | 2016 | 828 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2007 | 8547 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7581 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4853 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2015 | 1699 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8631 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 248 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2014 | 1149 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6863 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
Antibodies, Neutralizing | 2 | 2010 | 1943 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10766 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2571 | 0.020 |
Why?
|
Observation | 1 | 2011 | 310 | 0.020 |
Why?
|
Genetic Testing | 1 | 2003 | 3537 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14605 | 0.020 |
Why?
|
Virus Shedding | 1 | 2010 | 111 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2010 | 211 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2010 | 105 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3522 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 794 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1909 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2010 | 343 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 598 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 681 | 0.020 |
Why?
|
Proteins | 1 | 2003 | 6032 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 353 | 0.020 |
Why?
|
Hemoglobins | 1 | 2014 | 1525 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 1858 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 229 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1893 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6374 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9486 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1001 | 0.020 |
Why?
|
Antigens, CD1d | 1 | 2008 | 228 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2811 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 270 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1126 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2013 | 2416 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1606 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2010 | 673 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2122 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11121 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8320 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3597 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4544 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 823 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1505 | 0.010 |
Why?
|
Serologic Tests | 1 | 2007 | 381 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 2919 | 0.010 |
Why?
|
Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
Temperature | 1 | 2011 | 2226 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2005 | 641 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6567 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 2004 | 6310 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.010 |
Why?
|
Consensus | 1 | 2013 | 3123 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23445 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14666 | 0.010 |
Why?
|
Drug Combinations | 1 | 2008 | 2048 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1720 | 0.010 |
Why?
|
Autoantibodies | 1 | 2010 | 2116 | 0.010 |
Why?
|
Bone Marrow | 1 | 2012 | 2911 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81525 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 8002 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8654 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14414 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5791 | 0.010 |
Why?
|
DEAD-box RNA Helicases | 1 | 2003 | 384 | 0.010 |
Why?
|
Education, Medical | 1 | 2012 | 1725 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4124 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2003 | 1991 | 0.010 |
Why?
|
Musculoskeletal Diseases | 1 | 2006 | 598 | 0.010 |
Why?
|
Risk Management | 1 | 2003 | 558 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20098 | 0.010 |
Why?
|
Myocardium | 1 | 2012 | 4726 | 0.010 |
Why?
|
Graft Rejection | 1 | 2011 | 4445 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18252 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9420 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2010 | 3548 | 0.010 |
Why?
|
Epitopes | 1 | 2003 | 2503 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15936 | 0.010 |
Why?
|
Animals | 2 | 2020 | 168459 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2003 | 2358 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4303 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9326 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11076 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2522 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 2416 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36426 | 0.010 |
Why?
|
Women's Health | 1 | 2003 | 2065 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2004 | 2629 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2003 | 2639 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12441 | 0.010 |
Why?
|
Survivors | 1 | 2003 | 2371 | 0.010 |
Why?
|
Health Behavior | 1 | 2003 | 2643 | 0.010 |
Why?
|
Length of Stay | 1 | 2005 | 6425 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5127 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3889 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 26125 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11528 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2003 | 4016 | 0.000 |
Why?
|
Phenotype | 1 | 2005 | 16591 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 11903 | 0.000 |
Why?
|
Physicians | 1 | 2004 | 4591 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2003 | 4876 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15500 | 0.000 |
Why?
|
Depression | 1 | 2003 | 8124 | 0.000 |
Why?
|
Quality of Life | 1 | 2004 | 13367 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 21012 | 0.000 |
Why?
|